AA
IRON icon

AlphaCentric Advisors’s Disc Medicine IRON Stock Holding History

AlphaCentric Advisors’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
4,030
+58
+1% +$3.98K 0.25% 133
2026
Q1 		$254K Buy
3,972
+216
+6% +$15K 0.25% 125
2025
Q4 		$298K Buy
+3,756
New +$317K 0.3% 105

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AlphaCentric Advisors's IRON Position: Q2 2026 in Review

AlphaCentric Advisors increased its Disc Medicine (IRON) stake by 1.5% in Q2 2026, buying an estimated $3.98K and bringing the position to 4,030 shares worth $295K. The position accounts for 0.25% of the portfolio, ranked #133.

AlphaCentric Advisors first reported a position in IRON in Q4 2025 and has held it in 3 quarters since. The position peaked at $298K in Q4 2025. 217 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • AlphaCentric Advisors held 4,030 shares of Disc Medicine worth $295K as of Q2 2026.
  • AlphaCentric Advisors bought 58 Disc Medicine shares in Q2 2026, an estimated $3.98K.
  • Disc Medicine made up 0.25% of AlphaCentric Advisors's portfolio in Q2 2026, its #133 holding.
  • AlphaCentric Advisors first reported a position in Disc Medicine in Q4 2025 and has held it in 3 quarters since.
  • AlphaCentric Advisors's Disc Medicine position peaked at $298K in Q4 2025.
  • 217 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.